Matthew Dennis

Eli Lilly's Zepbound (tirzepatide) significantly reduced sleep apnoea severity in adults with obstructive sleep apnoea and obesity, notching up another win for the dual GIP and GLP-1 receptor agonist.

Having started the year by issuing conservative guidance , Novartis on Tuesday announced the first of its anticipated “beat-and-raise” quarters.

Sanofi's rilzabrutinib met the primary endpoint of a Phase III study in adults with persistent or chronic immune thrombocytopenia (ITP), setting up regulatory filings for the BTK inhibitor later this year.

Roche has cut 20% of new molecular entities from its pipeline since the third quarter of last year as it overhauls its portfolio to focus on “high-impact” projects.

Shares in Evotec plunged as much as 36% on Wednesday after the company provided an outlook for the current year that was well below consensus

Sanofi said Thursday that Dupixent remains on track to record sales of around €13 billion this year after posting strong growth in the first quarter

Bristol Myers Squibb on Thursday said that around 2200 staff will be impacted by cost-cutting measures that are designed to save about $1.5 billion by the end of 2025.

Xaira Therapeutics announced its launch with more than $1 billion in funding to support ambitions of developing new drugs through the end-to-end application of AI technologies.

Having posted a mixed bag in the first quarter, Gilead Sciences' attention is shifting to an FDA decision later this year on its recently-acquired drug seladelpar and a number of key Phase III readouts.

Pfizer announced Friday FDA approval of its gene therapy Beqvez (fidanacogene elaparvovec) to treat adults with moderate-to-severe haemophilia